Ma F, Yan M, Li W, Ouyang Q, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first
line treatment in patients with HER2 positive metastatic breast cancer (PHILA):
randomised, double blind, multicentre, phase 3 trial. BMJ 2023;383:e076065.
PMID: 37907210